vTv Therapeutics (VTVT) AI Stock Analysis

• Market Cap: $70.84M
• Dividend Yield: N/A
• Average Volume (3M): 3.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: -98.30%
• EPS Growth: 54.90%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.92
• Shares Outstanding: 2,617,215
• 10 Day Avg. Volume: 5,752
• 30 Day Avg. Volume: 3,842
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 4.27K
• Enterprise Value/Gross Profit: -1.86K
• Enterprise Value/Ebitda: -3.05
• 1Y Price Target: $36.00
• Price Target Upside: 62.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 38 Underperform
• Price Target: ―

vTv Therapeutics' overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock's attractiveness.

Positive Factors

Clinical Trial Progress

The resumption and acceleration of the Phase 3 trial for cadisegliatin could enhance vTv's market position by addressing unmet needs in diabetes management, potentially leading to future revenue growth and a stronger competitive edge.

Strategic Partnerships

vTv Therapeutics' strategy of generating revenue through partnerships and collaborations provides a sustainable business model by leveraging external expertise and resources, which can lead to steady cash flows and reduced financial risk.

Leadership Stability

The appointment of Barry Brown as interim CFO ensures continuity in financial leadership, which is crucial for maintaining strategic focus and operational stability during the search for a permanent CFO.

Negative Factors

Financial Instability

Persistent negative net income and cash flows highlight vTv's financial instability, which could hinder its ability to fund operations and invest in growth opportunities, posing a long-term risk to its business model.

Balance Sheet Weakness

The company's high liabilities and negative equity indicate a weak balance sheet, limiting its financial flexibility and increasing vulnerability to economic downturns, which could impact long-term sustainability.

Revenue Decline

The decline in revenue and unstable trends suggest challenges in maintaining consistent income streams, which could affect vTv's ability to invest in R&D and sustain competitive advantage over time.

vTv Therapeutics Business Overview & Revenue Model

Company Description

vTv Therapeutics (VTVT) is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company primarily operates in the pharmaceutical and biotechnology sectors, with a core emphasis on developing therapeutic solutions for metabolic diseases, including diabetes and inflammatory disorders. vTv Therapeutics leverages its proprietary technology platform, TTP Translational Technology, to advance its pipeline of innovative drug candidates.

How the Company Makes Money

vTv Therapeutics primarily generates revenue through partnerships and collaborations with other pharmaceutical companies. These collaborations often involve licensing agreements, wherein vTv licenses its proprietary drug candidates or technology platforms to partners in exchange for upfront payments, milestone payments based on development progress, and potential royalties on future sales. The company may also receive funding support through research grants and government incentives aimed at fostering innovation in the biopharmaceutical field. Additionally, vTv Therapeutics may engage in strategic alliances to co-develop and commercialize certain products, thereby sharing the financial risks and rewards associated with drug development.

vTv Therapeutics Financial Statement Overview

Summary

The financial performance of vTv Therapeutics is weak, with negative net income, negative cash flows, and a concerning balance sheet. The company faces significant financial challenges, underscored by negative equity and reliance on financing for liquidity.

Income Statement

vTv Therapeutics has shown unstable revenue trends with significant fluctuations over the years, highlighted by a decline in revenue in recent periods. The company exhibits negative net income consistently, leading to negative net profit margins. EBIT and EBITDA margins are also negative, indicating challenges in achieving operational profitability.

Balance Sheet

The company's balance sheet reveals high liabilities in comparison to equity, as reflected in negative stockholders' equity in multiple years, although there is some improvement in the latest year. The debt-to-equity ratio is concerning due to negative equity, posing significant financial risk. The equity ratio is negative, further emphasizing the financial instability.

Cash Flow

Operating cash flow is consistently negative, indicating ongoing cash burn. Free cash flow is also negative, suggesting insufficient cash generation to cover operating expenses. The company is reliant on financing activities for liquidity, which could be risky if external funding becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.00K	1.02M	0.00	2.02M	4.00M	6.41M
Gross Profit	-39.00K	928.00K	-90.00K	1.93M	3.92M	-4.60M
EBITDA	-23.82M	-22.52M	-25.86M	-24.77M	-17.52M	-12.02M
Net Income	-19.55M	-18.46M	-20.25M	-19.16M	-12.99M	-8.50M
Balance Sheet
Total Assets	26.45M	38.27M	11.02M	33.24M	25.47M	14.79M
Cash, Cash Equivalents and Short-Term Investments	25.92M	36.75M	9.45M	12.13M	13.41M	5.75M
Total Debt	79.00K	169.00K	529.00K	716.00K	932.00K	915.00K
Total Liabilities	24.04M	23.96M	29.57M	27.40M	10.25M	11.00M
Stockholders Equity	2.76M	12.20M	-24.68M	-10.74M	-9.74M	-80.10M
Cash Flow
Free Cash Flow	-22.02M	-25.31M	-19.08M	-16.04M	-19.31M	-18.00M
Operating Cash Flow	-22.02M	-25.31M	-19.08M	-16.02M	-19.31M	-18.00M
Investing Cash Flow	0.00	0.00	4.40M	-21.00K	0.00	0.00
Financing Cash Flow	2.42M	52.61M	12.00M	14.75M	26.98M	19.47M

vTv Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTVT, the sentiment is Positive. The current price of 22.18 is above the 20-day moving average (MA) of 19.55, above the 50-day MA of 17.04, and above the 200-day MA of 17.11, indicating a bullish trend. The MACD of 1.60 indicates Negative momentum. The RSI at 74.70 is Negative, neither overbought nor oversold. The STOCH value of 69.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTVT.

vTv Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLSD	42 Neutral	20.94M	-0.73	88.41%	―	-44.63%	26.79%
ADAP	41 Neutral	35.91M	-0.20	239.23%	―	-53.61%	-93.14%
VTVT	38 Underperform	$70.84M	―	-203.31%	―	-98.30%	54.90%
INZY	37 Underperform	104.07M	-1.00	-176.43%	―	―	-17.06%
JSPR	35 Underperform	65.06M	-0.39	―	―	―	-17.96%
BMEA	35 Underperform	122.59M	-0.68	―	―	―	22.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

vTv Therapeutics Corporate Events

vTv Therapeutics Appoints Barry Brown as Interim CFO

On April 11, 2025, vTv Therapeutics Inc. appointed Barry K. Brown as interim principal financial officer. Mr. Brown, who has been with the company since 2000, has previously served in various financial roles, including as chief accounting officer and interim principal financial officer. The company is actively searching for a permanent chief financial officer through an external process, and Mr. Brown’s appointment was made independently of any external arrangements.

Spark’s Take on VTVT Stock

According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.

vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.

To see Spark’s full report on VTVT stock, click here.

vTv Therapeutics Resumes Phase 3 Trial for Cadisegliatin

On March 31, 2025, vTv Therapeutics announced the resumption of their Phase 3 trial for cadisegliatin, following a clinical hold lifted on March 14, 2025. The trial, aimed at developing the first oral adjunct therapy for type 1 diabetes, will now be expedited by reducing its duration from 12 to 6 months, potentially enhancing the company’s market position and offering significant benefits to stakeholders by addressing high unmet needs in diabetes management.

vTv Therapeutics CFO Steven Tuch to Resign

On February 24, 2025, vTv Therapeutics announced that Steven Tuch, its Executive Vice President and Chief Financial Officer, plans to resign effective March 21, 2025. The company is actively seeking a successor through an external search, and Mr. Tuch’s departure is not due to any disagreements with the company or its auditors.